KR20010032800A - 신규 화합물 - Google Patents

신규 화합물 Download PDF

Info

Publication number
KR20010032800A
KR20010032800A KR1020007006117A KR20007006117A KR20010032800A KR 20010032800 A KR20010032800 A KR 20010032800A KR 1020007006117 A KR1020007006117 A KR 1020007006117A KR 20007006117 A KR20007006117 A KR 20007006117A KR 20010032800 A KR20010032800 A KR 20010032800A
Authority
KR
South Korea
Prior art keywords
pyridyl
yloxy
butyl
dione
formula
Prior art date
Application number
KR1020007006117A
Other languages
English (en)
Korean (ko)
Inventor
박스터앤드류
체샤이어데이비드
맥시날리토마스
몰티모어마이클
클라딩보엘데이비드
Original Assignee
다비드 에 질레스
아스트라제네카 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다비드 에 질레스, 아스트라제네카 유케이 리미티드 filed Critical 다비드 에 질레스
Publication of KR20010032800A publication Critical patent/KR20010032800A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020007006117A 1997-12-05 1998-12-01 신규 화합물 KR20010032800A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9704546-2 1997-12-05
SE9704546A SE9704546D0 (sv) 1997-12-05 1997-12-05 Novel compounds
PCT/SE1998/002190 WO1999029686A1 (en) 1997-12-05 1998-12-01 Novel compounds

Publications (1)

Publication Number Publication Date
KR20010032800A true KR20010032800A (ko) 2001-04-25

Family

ID=20409283

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007006117A KR20010032800A (ko) 1997-12-05 1998-12-01 신규 화합물

Country Status (16)

Country Link
EP (1) EP1037889A1 (pt)
JP (1) JP2001525406A (pt)
KR (1) KR20010032800A (pt)
CN (1) CN1284074A (pt)
AU (1) AU1791599A (pt)
BR (1) BR9813378A (pt)
CA (1) CA2312357A1 (pt)
EE (1) EE200000321A (pt)
HU (1) HUP0100731A3 (pt)
IL (1) IL136368A0 (pt)
NO (1) NO20002787L (pt)
PL (1) PL340837A1 (pt)
SE (1) SE9704546D0 (pt)
SK (1) SK8442000A3 (pt)
TR (1) TR200001544T2 (pt)
WO (1) WO1999029686A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901875D0 (sv) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
JP2002330787A (ja) * 2000-10-21 2002-11-19 Astrazeneca Ab 化学物質
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
ATE355273T1 (de) 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
BRPI0512781A (pt) 2004-06-29 2008-04-08 Pfizer Prod Inc método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila
US8546579B2 (en) 2006-03-16 2013-10-01 Evotec (Us) Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
BRPI0709596A2 (pt) 2006-03-16 2011-07-19 Renovis Inc compostos bicicloeteroarila como moduladores de p2x7 e seus usos
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為p2x7調節劑之雙環雜芳基化合物與其用途
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
KR101398264B1 (ko) * 2006-07-06 2014-05-26 글락소 그룹 리미티드 P2x7­수용체 길항제로서의 치환된 n­페닐메틸­5­옥소­프롤린­2­아미드 및 그의 사용 방법
GB0613473D0 (en) * 2006-07-06 2006-08-16 Glaxo Group Ltd Novel compounds
EP2124562B1 (en) 2007-03-09 2016-04-20 Second Genome, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
JP2010522711A (ja) * 2007-03-28 2010-07-08 グラクソ グループ リミテッド P2x7調節因子としてのピペリジノンカルボキサミド誘導体
EP2139875A2 (en) * 2007-03-29 2010-01-06 Glaxo Group Limited Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
EA200970912A1 (ru) 2007-04-03 2010-02-26 Глэксо Груп Лимитед Карбоксамидные производные имидазолидина в качестве модуляторов p2x7
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
CA2719745C (en) 2008-03-25 2016-07-05 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ATE541832T1 (de) 2009-04-14 2012-02-15 Affectis Pharmaceuticals Ag Neuartige p2x7r-antagonisten und ihre verwendung
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
CN102858741A (zh) 2010-05-14 2013-01-02 阿费克蒂斯制药股份公司 制备p2x7r拮抗剂的新方法
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
AU2018372136B2 (en) 2017-11-21 2022-01-27 Solventum Intellectual Properties Company Oral plant-based-oil-in-water emulsions and methods of use
CN111511348A (zh) 2017-12-20 2020-08-07 3M创新有限公司 口腔组合物及使用方法
EP3727336A1 (en) 2017-12-20 2020-10-28 3M Innovative Properties Company Oral compositions and methods of use

Also Published As

Publication number Publication date
BR9813378A (pt) 2000-10-10
EP1037889A1 (en) 2000-09-27
CA2312357A1 (en) 1999-06-17
EE200000321A (et) 2001-08-15
HUP0100731A2 (hu) 2002-05-29
IL136368A0 (en) 2001-06-14
TR200001544T2 (tr) 2000-11-21
AU1791599A (en) 1999-06-28
JP2001525406A (ja) 2001-12-11
SE9704546D0 (sv) 1997-12-05
PL340837A1 (en) 2001-02-26
HUP0100731A3 (en) 2002-08-28
WO1999029686A1 (en) 1999-06-17
NO20002787D0 (no) 2000-05-31
NO20002787L (no) 2000-08-01
CN1284074A (zh) 2001-02-14
SK8442000A3 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
KR20010032800A (ko) 신규 화합물
EP3661921B1 (en) Selective inhibitors of nlrp3 inflammasome
KR102050150B1 (ko) 융합-고리 화합물, 약학 조성물 및 이들의 용도
JP2022071149A (ja) Bruton型チロシンキナーゼ阻害薬
ES2274110T3 (es) Derivados de n-adamantilmetilo e intermedios como composiciones farmaceuticas y procedimientos para su preparacion.
EP1697308B1 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
AU781438B2 (en) VLA-4 inhibitor compounds
CN109867676B (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
TW202039471A (zh) Apol1抑制劑及其使用方法
KR20160090304A (ko) 우레아 유도체 또는 그의 약리학적으로 허용되는 염
CN105916852B (zh) 作为RORc调节剂的芳基磺内酰胺衍生物
KR20190057069A (ko) 신규한 jak1 선택적 억제제 및 그 용도
KR20090110950A (ko) (피라진 유도체) 퀴녹살린 화합물 및 이의 용도
TWI739779B (zh) 布魯頓氏酪胺酸激酶抑制劑及其使用方法
KR102591910B1 (ko) Ror 감마 (rory) 조정제
KR20180006450A (ko) 우레아 유도체 또는 그의 약리학상 허용되는 염
CA2869647A1 (en) Fused cyclopentyl antagonists of ccr2
IL273839B (en) Benzimidazole derivatives and their uses
KR20220118525A (ko) 벤즈이미다졸 유도체
JP2018519353A (ja) RORcモジュレーターとしてのアリールスルタム誘導体
EP3388430A1 (en) Compound, compound for use in the treatment of a pathological condition, a pharmaceutical composition and a method for preparing said compound
DE69907845T2 (de) Sulfonamid-Derivate
CN110945002B (zh) 作为RORγ抑制剂的双环化合物
TW202126649A (zh) 抗病毒吡唑并吡啶酮化合物
US20220009894A1 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid